LABCORP HOLDINGS INC. — Director's Dealing 2016

Mar 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2016-03-11

Reporting Person: Keller Deborah L (CEO, Covance Drug Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-11	Common Stock	M	1220	—	Acquired	12632	Direct
2016-03-11	Common Stock	F	374	$115.49	Disposed	12257	Direct
2016-03-11	Common Stock	M	11710	—	Acquired	23967	Direct
2016-03-11	Common Stock	F	4213	$115.49	Disposed	19754	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-11	Restricted Stock Unit	$	M	1220	Disposed		Common Stock (1220)	Direct
2016-03-11	Restricted Stock Unit	$	M	11710	Disposed		Common Stock (11710)	Direct

Footnotes

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2: Stock withholding to satisfy tax withholding obligations.

F3: The Restricted Stock Units vest in three equal annual installments beginning on 3/11/16.

F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

F5: The Restricted Stock Units vest in two equal annual installments beginning on 3/11/16.